The biological and pharmacological properties of some fibrinogen degradation products.
D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D000941:Antigens / Q000494:pharmacology*; D001920:Bradykinin / Q000494:pharmacology; D002199:Capillary Permeability / Q000187:drug effects; D004347:Drug Interactions; D004357:Drug Synergism; D004837:Epinephrine / Q000494:pharmacology; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D005341:Fibrinolysin / Q000494:pharmacology; D006168:Guinea Pigs; D006321:Heart / Q000187:drug effects; D007422:Intestines / Q000187:drug effects; D009119:Muscle Contraction / Q000187:drug effects; D009129:Muscle Tonus / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects; D010121:Oxytocin / Q000494:pharmacology; D051381:Rats; D013268:Stimulation, Chemical; D013997:Time Factors; D014599:Uterus / Q000187:drug effects
D000941:Antigens; D000804:Angiotensin II; D010121:Oxytocin; D005340:Fibrinogen; D005341:Fibrinolysin; D001920:Bradykinin; D004837:Epinephrine